Loading
NASDAQHealthcareBiotechnology
Latest quote
$31.73
+$2.37 · +8.07%
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Latest quote
$31.73
+$2.37 · +8.07%
After-hours
$31.73
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Day range
Current $31.73
52-week range
Current $31.73
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
56
Mixed
Risk
72
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Day range
Current $31.73
52-week range
Current $31.73
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 142K USD | — | — | — | — |
| Gross profit | −142K USD | — | — | — | — |
| Research and development | 35.38M USD | 18.59M USD | 9.45M USD | 25.18M USD | 60.8M USD |
| Selling, general, and administrative | 15.05M USD | 17.58M USD | 17.7M USD | 26.01M USD | 29.52M USD |
| Operating expenses | 50.29M USD | 57.29M USD | 34.62M USD | 52.02M USD | 90.32M USD |
| Interest income | 1.24M USD | 2.93M USD | 3.48M USD | 1.07M USD | 620K USD |
| Interest expense | — | — | — | 568K USD | — |
| Depreciation and amortization | 142K USD | 186K USD | 322K USD | 204K USD | 344K USD |
| Operating income | −50.43M USD | −57.29M USD | −34.62M USD | −52.02M USD | −90.32M USD |
| Net income | −83.98M USD | −56.83M USD | −31.39M USD | −51.66M USD | −89.95M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
